Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results

• Published in: Nature medicine Vol. 30; no. 5; pp. 1320 - 1329
• Main Authors: Bagley, Stephen J., Logun, Meghan, Fraietta, Joseph A., Wang, Xin, Desai, Arati S., Bagley, Linda J., Nabavizadeh, Ali, Jarocha, Danuta, Martins, Rene, Maloney, Eileen, Lledo, Lester, Stein, Carly, Marshall, Amy, Leskowitz, Rachel, Jadlowsky, Julie K., Christensen, Shannon, Oner, Bike Su, Plesa, Gabriela, Brennan, Andrea, Gonzalez, Vanessa, Chen, Fang, Sun, Yusha, Gladney, Whitney, Barrett, David, Nasrallah, MacLean P., Hwang, Wei-Ting, Ming, Guo-Li, Song, Hongjun, Siegel, Donald L., June, Carl H., Hexner, Elizabeth O., Binder, Zev A., O’Rourke, Donald M.
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.05.2024; Nature Publishing Group
• Subjects: 631/250/251; 631/67/1059/2325; 631/67/1922; 692/699/67/1922; Adult; Age; Aged; Anorexia; Biocompatibility; Biological activity; Biomedical and Life Sciences; Biomedicine; Brain Neoplasms - immunology; Brain Neoplasms - pathology; Brain Neoplasms - therapy; Cancer Research; Cerebrospinal fluid; Chimeric antigen receptors; Criteria; Dexamethasone; Eating disorders; Epidermal growth factor receptors; ErbB Receptors; Female; Glioblastoma; Glioblastoma - diagnostic imaging; Glioblastoma - immunology; Glioblastoma - pathology; Glioblastoma - therapy; Glioma; Growth factors; Humans; Immunotherapy, Adoptive - adverse effects; Immunotherapy, Adoptive - methods; Infectious Diseases; Injections, Spinal; Interleukin 1 receptor antagonist; Interleukin 1 receptors; Interleukin 13; Interleukin-13 Receptor alpha2 Subunit - immunology; Lymphocytes; Lymphocytes T; Magnetic resonance imaging; Male; Maximum Tolerated Dose; Metabolic Diseases; Middle Aged; Molecular Medicine; Muscular fatigue; Neoplasm Recurrence, Local - immunology; Neoplasm Recurrence, Local - pathology; Neurosciences; Neurotoxicity; Oncology; Patients; Receptors; Receptors, Chimeric Antigen - immunology; Tumors

Recurrent glioblastoma (rGBM) remains a major unmet medical need, with a median overall survival of less than 1 year. Here we report the first six patients with rGBM treated in a phase 1 trial of intrathecally delivered bivalent chimeric antigen receptor (CAR) T cells targeting epidermal growth fact...